20.12.2024 14:23:42 CET | Thor Medical ASA | Major shareholding notifications

Oslo, Norway, 20 December 2024: Reference is made to the stock exchange
announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a
private placement of new shares to be issued by the Company (the "Private
Placement") and a retail offering of new shares (the "PrimaryBid Offering"), and
stock exchange announcement by the Company on 12 December 2024 regarding
disclosure of share lending.

In connection with the registration of the share capital increase pertaining to
tranche 1 of the Private Placement and the PrimaryBid Offering, the manager has
redelivered a total of 45,632,920 borrowed shares to Scatec Innovation AS, close
associate of primary insider of the Company John Andersen.

During the term of the loan, and prior to the redelivery of the shares, Scatec
Innovation AS' shareholding in the Company was reduced to 18,785,012, equivalent
to approx. 6.70% of the issued share capital and votes. Upon redelivery of the
borrowed shares, Scatec Innovation AS' shareholding in the Company is
64,417,932, equivalent to approx. 22.97% of the issued share capital and votes.
Consequently, Scatec Innovation AS has crossed above the 20% threshold pursuant
to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.

In addition, Scatec Innovation AS has controlling interest in Scatec Invest II
AS and Scatec Invest IV AS, which holds 1,584,324 and 3,165,920 shares in the
Company, respectively. Scatec Innovation AS aggregated shareholding is thus
69,168,176, equivalent to approx. 24.7% of the shares and votes in the Company.

This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section
and 5-12.

Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, 
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no - 
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18370161/5450/Download%20announce
ment%20as%20PDF.pdf

Primary insider notification - re-delivery of lent shares.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18370161/5449/Primary%20insider%2
0notification%20-%20re-delivery%20of%20lent%20shares.pdf